---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000107"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T04:07:21.932653+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics Reports Updated Phase 1 Data for ELI-002 at ESMO Immuno-Oncology Congress 2024

## Summary
- Updated Phase 1 data show 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population (n=25).
- Strong correlation observed between T cell response and reduced risk of progression or death.
- Event-driven interim analysis from randomized Phase 2 trial of ELI-002 7P expected in first half of 2025.
- ELI-002 was well-tolerated with no Grade 3/4 adverse events or dose-limiting toxicities.

## SEC filing metadata
- accession: 0001601485-24-000107
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/0001601485-24-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/angn-20241212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000107
- JSON: https://secwatch.observer/filing/0001601485-24-000107.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.